Compugen (NASDAQ:CGEN) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Compugen (NASDAQ:CGEN) in a report released on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $4.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Compugen’s Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $0.37 EPS and FY2026 earnings at ($0.35) EPS.

CGEN has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Compugen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $4.00.

Compugen Trading Up 14.6%

Shares of Compugen stock opened at $1.88 on Wednesday. The company has a 50-day moving average of $1.58 and a two-hundred day moving average of $1.58. Compugen has a 12-month low of $1.13 and a 12-month high of $2.66. The stock has a market cap of $146.35 million, a PE ratio of -6.27 and a beta of 2.85.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Compugen had a negative return on equity of 53.60% and a negative net margin of 400.10%.The business had revenue of $1.89 million for the quarter, compared to analysts’ expectations of $1.47 million. On average, sell-side analysts forecast that Compugen will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. purchased a new position in Compugen during the second quarter worth about $56,000. R Squared Ltd acquired a new position in shares of Compugen during the 2nd quarter valued at about $71,000. Osaic Holdings Inc. lifted its holdings in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the period. Raymond James Financial Inc. boosted its position in shares of Compugen by 51.0% in the third quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 34,215 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 18,929 shares during the period. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.